Chemours price target raised to $32 from $30 at BMO Capital

BMO Capital analyst John McNulty raised the firm’s price target on Chemours to $32 from $30 and keeps an Outperform rating on the shares. The company’s notable management changes and accounting/control issues early in the year, along with volatility in various end-markets, have all raised questions about Chemours’ earnings power and the outlook for 2025, but the firm’s deep dive into the numerous moving pieces suggests “solid upside” to consensus in 2025, the analyst tells investors in a research note. BMO adds that it sees solid earnings growth, deleveraging and significant stock price appreciation for Chemours over the next 12 months.